Blueprint Medicines Corporation recently unveiled its 2025 corporate outlook and strategic vision for sustained growth, leveraging its established research, development, and commercial expertise. According to Kate Haviland, Chief Executive Officer…
Pharma Partners Gilead and LEO Pharma Forge Strategic Partnership to Advance Oral STAT6 Program for Inflammatory Diseases Pharma Partners Gilead Sciences and LEO Pharma today announced a groundbreaking strategic partnership…
WuXi AppTec Joins the Pharmaceutical Supply Chain Initiative to Strengthen Responsible Practices and Supply Chain Resilience Pharmaceutical Supply WuXi AppTec, a global leader providing comprehensive research, development, and manufacturing services…
Alnylam Pharmaceuticals Reports Preliminary 2024 Financials, 2025 Revenue and Pipeline Guidance Alnylam Pharmaceuticals Reports a global leader in RNA interference (RNAi) therapeutics, today released preliminary financial results for the fourth…
Ascendis Pharma A/S has provided a comprehensive update on its business and strategic roadmap for 2025, highlighting key milestones and growth opportunities. This update was presented by Jan Mikkelsen, President…
Introduction to Heart Failure and the Need for New Treatments Bayer has announced that it has submitted marketing authorization applications to both the U.S. Food and Drug Administration (FDA) and…
Regenerative Medicine Revolutionary Technologies Behind the Innovation Bio-Techne a renowned global leader in life science tools and reagents, has unveiled an impressive expansion to its R&D Systems AI-engineered designer protein…
Osimertinib: A Benchmark in Targeted Therapy Osimertinib The European Commission has granted approval for the combination of RYBREVANT® (amivantamab) and LAZCLUZE® (lazertinib) for the first-line treatment of adult patients with…
Formulation Results from the IRAKLIA Phase 3 Study Demonstrate Promise for Subcutaneous Sarclisa in Multiple Myeloma The Formulation IRAKLIA Phase 3 study has presented encouraging results for the investigational subcutaneous…
Biologics License Grifols Advances Fibrinogen Solution with U.S. FDA Submission Biologics License Grifols a global healthcare company and leading manufacturer of plasma-derived medicines, has announced the submission of a Biologics…
Ailux Biologics UCB\u2019s Strategic Collaboration with Ailux Biologics Ailux Biologics UCB, a leading global biopharmaceutical company, and XtalPi, an industry pioneer in AI-powered drug discovery, have announced a landmark license…
Roche Acquires Poseida Therapeutics: $9.00 per Share Tender Offer Completed Poseida Therapeutics Roche a global leader in the pharmaceutical and diagnostics industries, has announced the successful completion of its tender…